Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 2, 1997, Pages 170-174

  Honeybourne, David ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; DRUG CARRIER; LIPOSOME; MACROLIDE;

AEROSOL; HUMAN; LUNG; METABOLISM; RESPIRATORY TRACT INFECTION; REVIEW; TUBERCULOSIS;

4-QUINOLONES; AEROSOLS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG CARRIERS; HUMANS; LIPOSOMES; LUNG; MACROLIDES; RESPIRATORY TRACT INFECTIONS; TUBERCULOSIS;

EID: 0031085562     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199703000-00014     Document Type: Article

References (35)

1. Mouton JW, Vinks AA: Is continuous infusion of beta-lactam antibiotics worthwhile: efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996, 38:5-15.
2. Retsema JA, Girard AE, Girard D, Millisen WB: Relationship of high tissue concentrations of azithromycin to bacteriocidal activity and efficacy in vivo. J Antimicrob Chemother 1990, 25(suppl A):83-89.
3. Vallee E, Azoulay-Depuis E, Pocidalo JJ, Bergogne-Berezin E: Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. J Antimicrob Chemother 1991, 28(suppl C):39-44.
4. Azoulay-Depuis E, Vallee E, Bedos JP, Muffat-Joly M, Pocidalo JJ: Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother 1991, 35:1024-1028.
5. Edelstein PH, Edelstein MAC, Lehr KH, Ren J: In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 1996, 37:117-126.
6. Honeybourne D: Antibiotic penetration into lung tissues. Thorax 1994, 49:104-106.
7. Cook PJ, Andrews JM, Wise R, Honeybourne D: Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments. J Antimicrob Chemother 1996, 37:331-339.
8. Wise R, Honeybourne D: A review of the penetration of sparfloxacin into the respiratory tract and sinuses. J Antimicrob Chemother 1996, 37(suppl A):57-63. This review details lung penetration after single and multiple doses of sparfloxacin and compares other quinolones. High levels in alveolar macrophages and ELF suggest likely efficacy against S. pneumoniae. Information on bronchial mucosal levels is also included.
9. Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH: Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996, 40:2375-2379.
10. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, Segev S, Wijnands G: Treatment of community-acquired pneumonia: A randomised comparison of sparfloxacin amoxycillin-clavulanic acid and erythromycin. Eur Respir J 1995, 8:1999-2000. This comparison of three antibiotic regimens given to 808 patients with community-acquired pneumonia showed equivalent clinical success rates (80% to 87%) and similar overall success rates for the eradication of S. pneumoniae and H. influenzae infections.
11. Cook PJ, Andrews JM, Wise R, Honeybourne D, Moudgil H: Concentrations of OPC-17116: a new fluoroquinolone antibacterial in serum and lung compartments. J Antimicrob Chemother 1995, 35:317-326.
12. Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, Clement JJ: Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxyclarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990, 34:1407-1413.
13. Conte Jr JE, Golden J, Duncan S, McKenna E, Lin E, Zurlinden E: Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 1996, 40:1617-1622. Azithromycin, clarithromycin, and ciprofloxacin all penetrated well into alveolar cells, but only clarithromycin was detectable in the ELF. Conclusions are limited, however, because of the single-dose design of the study.
14. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D: Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990, 3:886-890.
15. Olsen KM, San Pedro GS, Gann L, Gubbins PO, Halinski DM, Campbell Jr GD: Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996, 40:2582-2585. In this multiple-dose study of azithromycin in 25 volunteers, antibiotic was detectable in the ELF for up to 7 days and in the alveolar macrophages for 21 days after the first dose. This evidence supports the likely efficacy of azithromycin given as a 5-day dosage schedule for pulmonary infections.
16. Braga PC, Dal Sasso M, Maci S, Bondiolotti G, Fonti E, Reggio S. Penetration of brodimoprim into human neutrophils and intracellular activity. Antimicrob Agents Chemother 1996, 40:2392-2398.
17. Wildfeuer A, Laufen H, Zimmermann T: Uptake of azithromycin by various cells and its intracellular activity under in vitro conditions. Antimicrob Agents Chemother 1996, 40:75-79.
18. Tomazic JM, Maticic M, Kotnik V, Simcic S, Wraber B, Zakotnik B: Ex vivo effect of azithromycin in human leukocyte bactericidal functions [letter]. Antimicrob Agents Chemother 1995, 39:1906.
19. Girard AE, Cimochowski CR, Faiella JA: Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localised infection. J Antimicrob Chemother 1996, 37(suppl C):9-19. Animals models given oral azithromycin showed concentrations of antibiotic at the site of infection to be greatly increased compared with a control group with little or no inflammation. A mechanism of cellular delivery of azithromycin was proposed.
20. Fujii T, Kadota J, Kawakami K, Iida K, Shirai R, Kaseda M, Kawamoto S, Kohno S: Long-term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995, 50:1246-1252.
21. Truffot-Pernot C, Lounis N, Grosset JH, Ji B: Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995, 39:2827-2828.
22. Luna-Herrera J, Reddy VM, Daneluzzi D, Gangadharam PJR: Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 1995, 39:2692-2695.
23. Bermudez LE, Kolonoski P, Young LS: Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice. Antimicrob Agents Chemother 1996, 40:1033-1035.
24. Wallace RJ, Brown BA, Griffith DE, Girard WM, Murphy DT: Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996, 153:1766-1772. In this study of 50 HIV-negative patients, 77% had a successful outcome using clarithromycin. Clarithromycin-containing regimens were suggested to be superior to older non-clarithromycin-containing treatments.
25. Pellegrin I, Maugein J, Lapeyre C, Barbeau P, Leng B, Pellegrin J-L: Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin alone and in combination, against Mycobacterium avium complex in human macrophages. J Antimicrob Chemother 1996, 37:501-510.
26. Ewig S, Schafer H, Rockstroh JK, Pickenhain A, Luderitz B: Effect of long-term primary aerosolized pentamidine prophylaxis on breakthrough Pneumocystis carinii pneumonia. Eur Respir J 1996, 9:1006-1012. There was a higher incidence of upper-lobe infiltrates compared with other sites on chest radiographs in patients receiving primary pentamidine prophylaxis compared with those not receiving prophylaxis.
27. Mukhopadhyay S, Singh M, Cater JI, Ogston S, Franklin M, Olver RE: Nebulised antipseudomonal therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 1996, 51:364-368. This meta-analysis of five studies showed benefit from nebulized therapy. The endpoints that improved were the number of infective exacerbations, bacterial load, and spirometry.
28. Davis PB, Drumm M, Konstan MW: Cystic fibrosis. Am J Respir Crit Care Med 1996, 154:1229-1256.
29. Bergogne-Berezin E: Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree. Infection 1987, 15:288-294.
30. Le Conte P, Potel G, Peltier P, Horeau D, Caillon J, Juvin M-E, Kergueris M-F, Bugnon D, Baron D: Lung distribution and pharmacokinetics of aerosolised tobramycin. Am Rev Respir Dis 1993, 147:1279-1282.
31. Klastersky J, Carpentier-Meunier F, Kahan-Coppens L, Thijs JP: Endotracheally administered antibiotics for gram-negative bronchopneumonia. Chest 1979, 75:586-591.
32. Hashimoto S, Wolfe E, Guglielmo B, Shanks R, Sundelof J, Pittet JF, Thomas E, Wiener-Kronish J: Aerosolization of imipenem/cilastatin prevents pseudomonas-induced acute lung injury. J Antimicrob Chemother 1996, 38:809-818. In this comparison of the effects of aerosol and intravenous delivery of imipenem/cilastatin in an animal model, the aerosol-treated group had much less bacterial-induced lung injury.
33. Purcell IF, Corris PA: Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Thorax 1995, 50:1321-1323.
34. Oh Y-K, Nix DE, Straubinger RM: Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob Agents Chemother 1995, 39:2104-2111.
35. Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M, Franchini C, Concia E: Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996, 38:865-869. A 1-hour infusion of 1 g of vancomycin did not achieve sustained adequate lung concentrations over the subsequent 12 hours. Continuous infusion may be more effective.